STAT

Moderna to pay Roivant up to $2.25 billion to settle patent lawsuit behind mRNA vaccines

A settlement provides a massive windfall for Arbutus and Roivant and avoids a worst-case scenario for Moderna.

Moderna rises on $2.25 billion settlement, clearing COVID vaccine patent dispute overhang

By Puyaan Singh March 4 (Reuters) - Moderna shares rose 9% on Wednesday after it settled a long-running legal battle over the technology that made its COVID-19 vaccine possible, removing an overhang ...

Moderna shares rise on $2.25-billion settlement over COVID-19 vaccine technology

Moderna will pay US$950-million upfront in July, 2026, with an additional US$1.3-billion contingent on the outcome of a separate legal appeal, while not owing royalties for the technology in its ...
Investing News Network on MSN

Moderna to pay US$950 million to settle COVID-19 vaccine patent dispute

Moderna (NASDAQ:MRNA) has agreed to pay US$950 million to resolve a long-running patent dispute tied to the technology used ...
AOL

Moderna rises as up to $2.25 billion settlement for COVID vaccine patent dispute to remove overhang

March 4 (Reuters) - Moderna shares rose 10% on Wednesday after the company settled a long-running legal battle over the ‌technology that made its COVID-19 vaccine possible, removing an overhang and ...